Clinical trial • Phase II • Neurology
Clinical trial in Parkinson's disease
Phase II trial for Parkinson's disease. 40 participants.
Overview
- Trial Therapeutic Area
- Neurology
- Trial Disease
- Parkinson's disease
- Trial Stage
- Phase II
Key dates
- Initial CTIS Submission Date
- 03-03-2026
- First CTIS Authorization Date
- 27-03-2026
Trial design
Phase II trial across 1 site in Czechia.
- Target Sample Size
- 40
- Trial Duration For Participant
- 57
Eligibility
Recruits 40 Vulnerable population selected: true (isVulnerablePopulationSelected). Population: Healthy volunteers. No details on consent or assent handling are provided in the available documents..
- Vulnerable Population
- Vulnerable population selected: true (isVulnerablePopulationSelected). Population: Healthy volunteers. No details on consent or assent handling are provided in the available documents.
Recruitment
- Planned Sample Size
- 40
- Recruitment Window Months
- 2
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 40
Czechia
- Earliest CTIS Part Ii Submission Date
- 03-03-2026
- Latest Decision Or Authorization Date
- 27-03-2026
- Processing Time Days
- 24
- Number Of Sites
- 1
- Number Of Participants
- 40
Sites
- Site Name
- Cepha s.r.o.
- Department Name
- clinic
- Contact Person Name
- Jolana Herejkova
- Contact Person Email
- herejkova@cepha.cz
Sponsor
Primary sponsor
- Full Name
- Orion Corporation
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Finland
Related trials
Other published trials that may interest you.